KROS Keros Therapeutics, Inc.
Nasdaq · SEC CIK 1664710 · EDGAR
- Bought, last 12 months
- $75.8K 6 purchases by 1 insiders
- Sold, last 12 months
- $181.16M 14 sales by 11 insiders
- Filings on record
- 126 since 2021-07-06, latest 2026-08-20 16:10
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Schneeberger Daniel | 10% | — | $95.66M |
| Pontifax (China) IV L.P. | 10% | — | $84.98M |
| Cho Esther | SVP, GC | — | $123.7K |
| Seehra Jasbir | CEO, Dir | — | $113.4K |
| Lerner Lorena Raquel | CSO | — | $100.0K |
| Regnante Keith | CFO | — | $77.5K |
| BIENAIME JEAN JACQUES | Dir | $75.8K | — |
| Knowles Julius | Dir | — | $28.2K |
| Farzan Nima | Dir | — | $28.2K |
| Seth Alpna | Dir | — | $28.1K |
Transactions 98
Purchase Sale Sale after option exercise All abbreviations
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-20 16:10 | 2026-08-18 | KROS | Tanini Annita | VP, Corp. Ctrl, Fin | S - Sale | $10.29 | -1,224 | 45.1K | -3% | -$12.6K | |
| 2026-08-20 16:10 | 2026-08-18 | KROS | Lerner Lorena Raquel | CSO | S - Sale | $10.29 | -3,568 | 27.6K | -11% | -$36.7K | |
| 2026-08-20 16:10 | 2026-08-18 | KROS | Cho Esther | CLO | S - Sale | $10.29 | -4,485 | 35.8K | -11% | -$46.2K | |
| T | 2026-08-20 16:10 | 2026-08-18 | KROS | Newton Charles W. | Dir | S - Sale | $10.30 | -551 | 12.1K | -4% | -$5,675 |
| T | 2026-08-19 16:10 | 2026-08-17 | KROS | BIENAIME JEAN JACQUES | Dir | P - Purchase | $10.27 | +1,000 | 19.6K | +5% | +$10.3K |
| T | 2026-07-17 16:10 | 2026-07-15 | KROS | BIENAIME JEAN JACQUES | Dir | P - Purchase | $10.61 | +1,000 | 18.6K | +6% | +$10.6K |
| D | 2026-07-06 16:31 | 2026-07-01 | KROS | Prener Anne | Dir | A - Grant | $0.00 | +13.8K | 13.8K | New | $0 |
| T | 2026-06-17 16:55 | 2026-06-15 | KROS | BIENAIME JEAN JACQUES | Dir | P - Purchase | $10.19 | +1,000 | 17.6K | +6% | +$10.2K |
| T | 2026-06-15 16:15 | 2026-06-11 | KROS | Newton Charles W. | Dir | S - Sale | $10.04 | -550 | 12.7K | -4% | -$5,522 |
| T | 2026-06-08 16:37 | 2026-06-04 | KROS | Farzan Nima | Dir | S - Sale | $10.73 | -2,625 | 9,767 | -21% | -$28.2K |
| T | 2026-06-08 16:36 | 2026-06-04 | KROS | Knowles Julius | Dir | S - Sale | $10.73 | -2,625 | 11.0K | -19% | -$28.2K |
| D | 2026-06-05 17:20 | 2026-06-03 | KROS | Seth Alpna | Dir | A - Grant | $0.00 | +7,142 | 12.4K | +136% | $0 |
| T | 2026-06-05 16:15 | 2026-06-04 | KROS | Seth Alpna | Dir | S - Sale | $10.72 | -2,625 | 9,767 | -21% | -$28.1K |
| D | 2026-06-05 16:15 | 2026-06-03 | KROS | GRAY MARY ANN | Dir | A - Grant | $0.00 | +7,142 | 12.4K | +136% | $0 |
| D | 2026-06-05 16:15 | 2026-06-03 | KROS | Farzan Nima | Dir | A - Grant | $0.00 | +7,142 | 12.4K | +136% | $0 |
| D | 2026-06-05 16:15 | 2026-06-03 | KROS | BIENAIME JEAN JACQUES | Dir | A - Grant | $0.00 | +7,142 | 16.6K | +76% | $0 |
| D | 2026-06-05 16:15 | 2026-06-03 | KROS | Knowles Julius | Dir | A - Grant | $0.00 | +7,142 | 13.6K | +111% | $0 |
| T | 2026-05-19 16:15 | 2026-05-15 | KROS | BIENAIME JEAN JACQUES | Dir | P - Purchase | $10.58 | +1,000 | 9,450 | +12% | +$10.6K |
| T | 2026-04-17 16:15 | 2026-04-15 | KROS | BIENAIME JEAN JACQUES | Dir | P - Purchase | $11.70 | +1,000 | 8,450 | +13% | +$11.7K |
| D | 2026-04-06 16:15 | 2026-04-02 | KROS | Seehra Jasbir | CEO, Dir | M - OptEx | $0.3 | +55.0K | 440.7K | +14% | +$16.5K |
| D | 2026-03-11 | 2026-03-09 | KROS | Newton Charles W. | Dir | A - Grant | $0.00 | +13.2K | 13.2K | New | $0 |
| 2026-03-11 | 2026-03-09 | KROS | BIENAIME JEAN JACQUES | Dir | P - Purchase | $11.21 | +2,000 | 7,450 | +37% | +$22.4K | |
| 2026-02-20 | 2026-02-18 | KROS | Regnante Keith | CFO | S - Sale | $16.35 | -4,739 | 39.3K | -11% | -$77.5K | |
| 2026-02-20 | 2026-02-19 | KROS | Seehra Jasbir | CEO, Dir | S - Sale | $16.17 | -7,015 | 385.7K | -2% | -$113.4K | |
| 2026-02-20 | 2026-02-18 | KROS | Lerner Lorena Raquel | CSO | S - Sale | $16.35 | -3,873 | 31.1K | -11% | -$63.3K | |
| 2026-02-20 | 2026-02-18 | KROS | Cho Esther | SVP, GC | S - Sale | $16.35 | -4,745 | 39.8K | -11% | -$77.6K | |
| MI | 2025-12-18 | 2025-11-21 | KROS | Knowles Julius | Dir | D - Sale to Iss | $17.75 | -322.0K | 102.2K | -76% | -$5.72M |
| MI | 2025-12-18 | 2025-11-21 | KROS | OrbiMed Genesis GP LLC | Dir | D - Sale to Iss | $17.75 | -214.5K | 45.1K | -83% | -$3.81M |
| MI | 2025-12-18 | 2025-11-21 | KROS | GORDON CARL L | Dir | D - Sale to Iss | $17.75 | -214.5K | 759.2K | -22% | -$3.81M |
| MI | 2025-10-17 | 2025-10-15 | KROS | Pontifax (China) IV L.P. | 10% | S - Sale | $17.75 | -4.79M | 0 | -100% | -$84.98M |
| MI | 2025-10-15 | 2025-10-15 | KROS | Schneeberger Daniel | 10% | S - Sale | $17.75 | -5.39M | 0 | -100% | -$95.66M |
| 2025-09-05 | 2025-09-03 | KROS | Seehra Jasbir | CEO, Dir | A - Grant | $0.00 | +90.5K | 392.7K | +30% | $0 | |
| DMI | 2025-06-24 | 2025-06-20 | KROS | Schneeberger Daniel | 10% | X - OptEx | $69.41 | -1,700 | 743.4K | -0.2% | -$118.0K |
| D | 2025-06-06 | 2025-06-04 | KROS | Farzan Nima | Dir | A - Grant | $0.00 | +5,250 | 5,250 | New | $0 |
| D | 2025-06-06 | 2025-06-04 | KROS | Knowles Julius | Dir | A - Grant | $0.00 | +5,250 | 6,441 | +441% | $0 |
| D | 2025-06-06 | 2025-06-04 | KROS | Kariv Tomer | Dir, 10% | A - Grant | $0.00 | +5,250 | 5,250 | New | $0 |
| D | 2025-06-06 | 2025-06-04 | KROS | Nussbaum Ran | Dir, 10% | A - Grant | $0.00 | +5,250 | 5,250 | New | $0 |
| D | 2025-06-06 | 2025-06-04 | KROS | BIENAIME JEAN JACQUES | Dir | A - Grant | $0.00 | +5,250 | 5,450 | +2,625% | $0 |
| D | 2025-06-06 | 2025-06-04 | KROS | GRAY MARY ANN | Dir | A - Grant | $0.00 | +5,250 | 5,250 | New | $0 |
| D | 2025-06-06 | 2025-06-04 | KROS | GORDON CARL L | Dir | A - Grant | $0.00 | +5,250 | 5,250 | New | $0 |
| D | 2025-06-06 | 2025-06-04 | KROS | Seth Alpna | Dir | A - Grant | $0.00 | +5,250 | 5,250 | New | $0 |
| DMI | 2025-04-11 | 2025-04-09 | KROS | ADAR1 Partners, LP | 10% | P - Purchase | $10.13 | +934.3K | 4.39M | +27% | +$9.47M |
| D | 2025-04-07 | 2025-04-04 | KROS | Seehra Jasbir | CEO, Dir | M - OptEx | $0.3 | +49.4K | 302.2K | +20% | +$14.8K |
| 2025-02-19 | 2025-02-18 | KROS | Rovaldi Christopher | COO | A - Grant | $0.00 | +60.0K | 60.0K | New | $0 | |
| 2025-02-19 | 2025-02-18 | KROS | CHYUNG YUNG H. | Chief Medical Off | A - Grant | $0.00 | +44.0K | 44.0K | New | $0 | |
| 2025-02-19 | 2025-02-18 | KROS | Regnante Keith | CFO | A - Grant | $0.00 | +44.0K | 44.0K | New | $0 | |
| A | 2025-01-24 | 2024-01-04 | KROS | Regnante Keith | CFO | S - Sale+OE | $45.29 | -40.0K | 0 | -100% | -$1.81M |
| A | 2025-01-24 | 2024-01-04 | KROS | Regnante Keith | CFO | M - OptEx | $16.00 | +40.0K | 40.0K | New | +$640.0K |
| MI | 2024-08-15 | 2024-08-13 | KROS | GORDON CARL L | Dir | S - Sale | $44.01 | -250.0K | 119.5K | -68% | -$11.00M |
| MI | 2024-08-15 | 2024-08-13 | KROS | OrbiMed Genesis GP LLC | Dir | S - Sale | $44.01 | -250.0K | 899.2K | -22% | -$11.00M |
| D | 2024-01-08 | 2023-11-04 | KROS | Regnante Keith | CFO | M - OptEx | $16.00 | +40.0K | 40.0K | New | +$640.0K |
| D | 2024-01-08 | 2023-11-04 | KROS | Regnante Keith | CFO | S - Sale+OE | $45.29 | -40.0K | 0 | -100% | -$1.81M |
| DM | 2023-06-12 | 2023-06-08+ | KROS | Regnante Keith | CFO | M - OptEx | $16.00 | +40.0K | 20.0K | New | +$640.0K |
| DM | 2023-06-12 | 2023-06-08+ | KROS | Regnante Keith | CFO | S - Sale+OE | $46.61 | -40.0K | 2,699 | -94% | -$1.86M |
| D | 2023-04-11 | 2023-04-08 | KROS | Seehra Jasbir | CEO, Dir | M - OptEx | $0.48 | +4,000 | 252.9K | +2% | +$1,920 |
| 2023-01-20 | 2020-04-13 | KROS | Knowles Julius | Dir | P - Purchase | $20.98 | +1,191 | 1,191 | New | +$25.0K | |
| DMI | 2022-11-30 | 2022-11-29 | KROS | Nussbaum Ran | Dir, 10% | X - OptEx | $0.00 | -7,176 | 1.12M | -0.6% | $0 |
| DMI | 2022-11-30 | 2022-11-29 | KROS | Pontifax Late Stage GP Ltd. | 10% | X - OptEx | $0.00 | -7,176 | 1.12M | -0.6% | $0 |
| DMI | 2022-11-30 | 2022-11-29 | KROS | Kariv Tomer | Dir, 10% | X - OptEx | $0.00 | -7,176 | 1.12M | -0.6% | $0 |
| D | 2022-07-19 | 2022-07-15 | KROS | Lachey Jennifer | CSO | M - OptEx | $0.3 | +46.0K | 141.1K | +48% | +$13.8K |
| D | 2022-07-19 | 2022-07-15 | KROS | Lachey Jennifer | CSO | S - Sale+OE | $30.00 | -46.0K | 95.1K | -33% | -$1.38M |
| D | 2022-07-15 | 2022-07-13 | KROS | Lachey Jennifer | CSO | M - OptEx | $0.3 | +1,916 | 93.2K | +2% | +$574.80 |
| D | 2022-07-15 | 2022-07-13 | KROS | Lachey Jennifer | CSO | S - Sale+OE | $30.00 | -1,916 | 95.1K | -2% | -$57.5K |
| D | 2022-06-14 | 2022-06-14 | KROS | Lachey Jennifer | CSO | M - OptEx | $0.3 | +9,400 | 95.1K | +11% | +$2,820 |
| D | 2022-06-10 | 2022-06-09 | KROS | Seehra Jasbir | CEO, Dir | M - OptEx | $0.3 | +5,000 | 248.9K | +2% | +$1,500 |
| D | 2022-05-13 | 2022-05-11 | KROS | Lachey Jennifer | CSO | M - OptEx | $0.3 | +5,300 | 91.0K | +6% | +$1,590 |
| DM | 2022-05-13 | 2022-05-11 | KROS | Lachey Jennifer | CSO | S - Sale+OE | $41.90 | -5,300 | 85.7K | -6% | -$222.0K |
| DM | 2022-04-13 | 2022-04-11 | KROS | Lachey Jennifer | CSO | S - Sale+OE | $62.77 | -5,300 | 86.3K | -6% | -$332.7K |
| D | 2022-04-13 | 2022-04-11 | KROS | Lachey Jennifer | CSO | M - OptEx | $0.3 | +5,300 | 91.0K | +6% | +$1,590 |
| D | 2022-04-08 | 2022-04-06 | KROS | Rovaldi Christopher | COO | S - Sale+OE | $65.00 | -1,728 | 0 | -100% | -$112.3K |
| D | 2022-04-08 | 2022-04-06 | KROS | Rovaldi Christopher | COO | M - OptEx | $16.00 | +1,728 | 1,728 | New | +$27.6K |
| D | 2022-04-06 | 2022-04-04 | KROS | Lachey Jennifer | CSO | M - OptEx | $0.3 | +7,950 | 93.7K | +9% | +$2,385 |
| D | 2022-04-06 | 2022-04-04 | KROS | Lachey Jennifer | CSO | S - Sale+OE | $60.00 | -7,950 | 85.7K | -8% | -$477.0K |
| DM | 2022-04-05 | 2022-04-01 | KROS | Rovaldi Christopher | COO | S - Sale+OE | $57.49 | -864 | 0 | -100% | -$49.7K |
| D | 2022-04-05 | 2022-04-01 | KROS | Rovaldi Christopher | COO | M - OptEx | $16.00 | +864 | 864 | New | +$13.8K |
| DM | 2022-03-15 | 2022-03-11 | KROS | Lachey Jennifer | CSO | S - Sale+OE | $53.38 | -2,650 | 85.7K | -3% | -$141.4K |
| D | 2022-03-15 | 2022-03-11 | KROS | Lachey Jennifer | CSO | M - OptEx | $0.3 | +2,650 | 88.3K | +3% | +$795 |
| DM | 2022-02-15 | 2022-02-11 | KROS | Lachey Jennifer | CSO | S - Sale+OE | $52.06 | -2,650 | 85.9K | -3% | -$138.0K |
| D | 2022-02-15 | 2022-02-11 | KROS | Lachey Jennifer | CSO | M - OptEx | $0.3 | +2,650 | 88.3K | +3% | +$795 |
| D | 2022-01-13 | 2022-01-11 | KROS | Lachey Jennifer | CSO | M - OptEx | $0.3 | +2,650 | 88.3K | +3% | +$795 |
| DM | 2022-01-13 | 2022-01-11 | KROS | Lachey Jennifer | CSO | S - Sale+OE | $53.75 | -2,650 | 88.0K | -3% | -$142.4K |
| D | 2022-01-07 | 2022-01-05 | KROS | Lachey Jennifer | CSO | M - OptEx | $0.3 | +2,650 | 88.3K | +3% | +$795 |
| D | 2022-01-07 | 2022-01-05 | KROS | Lachey Jennifer | CSO | S - Sale+OE | $60.00 | -2,650 | 85.7K | -3% | -$159.0K |
| MI | 2022-01-05 | 2022-01-03+ | KROS | Knowles Julius | Dir | S - Sale | $57.84 | -47.7K | 355.4K | -12% | -$2.76M |
| DM | 2021-12-15 | 2021-12-13+ | KROS | Lachey Jennifer | CSO | S - Sale+OE | $50.40 | -2,650 | 85.7K | -3% | -$133.6K |
| DM | 2021-12-15 | 2021-12-13+ | KROS | Lachey Jennifer | CSO | M - OptEx | $0.3 | +2,650 | 87.6K | +3% | +$795 |
| MI | 2021-12-03 | 2021-12-01+ | KROS | Knowles Julius | Dir | S - Sale | $54.09 | -47.7K | 387.3K | -11% | -$2.58M |
| DM | 2021-11-12 | 2021-11-10+ | KROS | Lachey Jennifer | CSO | S - Sale+OE | $59.91 | -21.2K | 90.3K | -19% | -$1.27M |
| DM | 2021-11-12 | 2021-11-10+ | KROS | Lachey Jennifer | CSO | M - OptEx | $0.3 | +21.2K | 101.6K | +26% | +$6,360 |
| D | 2021-11-05 | 2021-11-04 | KROS | Lachey Jennifer | CSO | M - OptEx | $0.3 | +10.6K | 96.3K | +12% | +$3,180 |
| D | 2021-11-05 | 2021-11-04 | KROS | Lachey Jennifer | CSO | S - Sale+OE | $50.00 | -10.6K | 85.7K | -11% | -$530.0K |
| MI | 2021-11-03 | 2021-11-01+ | KROS | Knowles Julius | Dir | S - Sale | $42.12 | -47.7K | 270.3K | -15% | -$2.01M |
| MI | 2021-10-21 | 2021-10-19+ | KROS | Knowles Julius | Dir | S - Sale | $38.20 | -8,598 | 290.6K | -3% | -$328.4K |
| MI | 2021-10-18 | 2021-10-14+ | KROS | Knowles Julius | Dir | S - Sale | $38.56 | -26.4K | 446.6K | -6% | -$1.02M |
| MI | 2021-10-05 | 2021-10-01+ | KROS | Knowles Julius | Dir | S - Sale | $40.10 | -12.7K | 450.8K | -3% | -$508.8K |
| MI | 2021-09-29 | 2021-09-27 | KROS | Knowles Julius | Dir | S - Sale | $41.17 | -95.3K | 327.7K | -23% | -$3.92M |
| D | 2021-08-18 | 2021-08-17 | KROS | Lachey Jennifer | CSO | M - OptEx | $0.3 | +1,293 | 85.7K | +2% | +$387.90 |
| MI | 2021-07-06 | 2021-07-01+ | KROS | Knowles Julius | Dir | S - Sale | $41.31 | -47.7K | 355.0K | -12% | -$1.97M |